Anti-Sema3A antibodies and their uses for treating eye or ocular diseases

US11267880B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Leo Thomas · Biberach, DE
• Rachel Rebecca Barrett · Bethel, US
• Kristin Laura BOVAT · Ridgefield, US
• Rajkumar Ganesan · Blue Bell, US
• Priyanka GUPTA · Danbury, US
• Fei HAN · Sandy Hook, US
• Dongmei LIU · Oxford, US
• Juergen PRESTLE · Biberach an der Riß, DE
• Sanjaya Singh · Sandy Hook, US
• Sathyadevi VENKATARAMANI · Blue Bell, US
• Helen Haixia Wu · Danbury, US
• Nina ZIPPEL · Biberach an der Riß, DE

Key dates

• Filing date: May 8, 2020
• Grant date: Mar 8, 2022
• Expiry date: Jun 15, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.